Monitoring and reassessing treatment for bile duct cancer
Part of Cancer clinical trials.
This study looks at how well current treatments work for bile duct cancer that cannot be removed with surgery. It also reassesses treatment plans to see if they can be improved based on new imaging or tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have cholangiocarcinoma (bile duct cancer) that is either inside the liver or at the hilum (where bile ducts meet the liver).
- Your cancer should be diagnosed as localized (has not spread far) and not removable with surgery at a specialized tumor board meeting.
- You must be considered medically able to receive tumor-directed drug therapy.
- You must be 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This study tests whether robot-assisted surgery is safe and effective for people with perihilar cholangiocarcinoma (a type of bile duct cancer). It may be a good fit for patients whose cancer has not spread and who are healthy enough for major surgery.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.